Bleomycin (DrugBank: Bleomycin)
4 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 96 | クローン病 | 1 |
| 278 | 巨大リンパ管奇形（頚部顔面病変） | 1 |
| 279 | 巨大静脈奇形（頚部口腔咽頭びまん性病変） | 2 |
| 280 | 巨大動静脈奇形（頚部顔面又は四肢病変） | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000031344 | 2020-05-01 | 2020-03-28 | Endoscopic Stricturotomy combined with local injection of bleomycin in the treatment of primary anorectal stricture in crohn's disease: a Prospective, double-blind, randomized controlled clinical study | Endoscopic Stricturotomy combined with local injection of bleomycin in the treatment of primary anorectal stricture in crohn's disease: a Prospective, double-blind, randomized controlled clinical study | Crohn's disease | Group 1:Endoscopic Stricturotomy;Group 2:Endoscopic Stricturotomy combined with local bleomycin injection; | The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine | NULL | Pending | Both | Group 1:35;Group 2:35; | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs031180265 | 10/08/2016 | 13/03/2019 | Study of bleomycin and OK-432 combined scletotherapy for LMs | Clinical study of bleomycin and OK-432 combined local injection sclerotherapy for intractable lymphatic malformations | Lymphangioma (lymphatic malformation, common or cystic lymphatic malformation), and other lymphatic lymphangioma, lymphatic malformation,;D18.1 | OK-432 and bleomycin slolution (0.05 kE / mL and 0.5 mg / mL, respectively) will be injected into the lesion with water-soluble contrast agent Maximum dose of bleomycin is 10 mg /dose and 5 mg/kgBW.Cumulative maximum dose in repeated treatment is 10 mg/kgBW | Fujino Akihiro | NULL | Not Recruiting | Not applicable | Not applicable | Both | 21 | N/A | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-001455-37-NO (EUCTR) | 21/12/2011 | 01/06/2011 | Prospective randomized interventional study in patients with venous malformations. | Prospective randomized interventional study. Compare the effect of bleomycin and Tetradecyl Sodium Sulphate (Fibrovein) in the treatment of venous malformations. Clinical neurological and neurophysiological study of a subpopulation of patients with venous malformations. | Venous malformation MedDRA version: 13.1;Level: LLT;Classification code 10047229;Term: Venous malformation NOS;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Bleomycin Baxter Product Name: Bleomycin Trade Name: Fibrovein 3% Product Name: Fibrovein 3% | Department of Radiology, Oslo University Hospital, Norway | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Norway | ||||
| 2 | NCT01347294 (ClinicalTrials.gov) | August 2011 | 11/4/2011 | Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations | Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations | Venous Malformation | Drug: Bleomycin;Drug: Fibrovein;Drug: Bleomycin + Fibrovein | Oslo University Hospital | NULL | Recruiting | 12 Years | 80 Years | All | 126 | Phase 4 | Norway |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-IOR-16008047 | 2016-03-01 | 2016-03-03 | Early intervention of extracranial arteriovenous malformations with bleomycin: a prospective, multicenter, single-blind, randomized, controlled clinical trial | Early intervention of extracranial arteriovenous malformations with bleomycin: a prospective, multicenter, single-blind, randomized, controlled clinical trial | extracranial arteriovenous malformations | bleomycin group:Intralesional Bleomycin Injection;Control group:No medicine; | Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine | NULL | Recruiting | Both | bleomycin group:80;Control group:40; | China | |||
| 2 | ChiCTR-OOB-15007258 | 2014-03-10 | 2015-10-23 | Early Intervention of Extracranial Arteriovenous Malformations with intralesional bleomycin injections: A Prospective Study | Early Intervention of Extracranial Arteriovenous Malformations with intralesional bleomycin injections: A Prospective Study | Arteriovenous Malformation | bleomycin group:intralesional adminstrated bleomycin ; | Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine | NULL | Recruiting | 2 | 60 | Both | bleomycin group:30; | China |